Transactions
15
Insider / Roivant Sciences Ltd.
Ramaswamy Vivek
Insider at Roivant Sciences Ltd.
- Company
- Roivant Sciences Ltd.
- Ticker
- ROIV
- First filing on record
- November 17, 2025
- Latest trade on record
- December 15, 2025
- SEC filings
- EDGAR ↗
Ramaswamy Vivek, Insider at Roivant Sciences Ltd., has disclosed 15 transactions in ROIV since November 17, 2025: 0 purchases (0 open-market buys) and 6 sales, worth about $292.9M at the reported prices. The latest was filed December 15, 2025, 0 days after the trade.
Open-market buys
0
Sales
6
Avg. disclosure lag
2.3d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Ramaswamy Vivek made no purchases and 6 sales worth $106M, plus 9 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Ramaswamy Vivek has traded 1 stock on record; the largest by dollars is ROIV.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 6 | 14,749,736 | $93.5M |
| S | Open-market sale | 6 | 4,958,348 | $105.9M |
| J | Other acquisition or disposal | 3 | 4,271,124 | $93.5M |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2025 | 15 | 0 | 6 · $105.9M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| ROIV | Option / conversion M | December 15, 2025 | December 15, 2025 | 0d | 832,453 | — | — | derivative | Form 4 ↗ | |
| ROIV | Option / conversion M | December 12, 2025 | December 15, 2025 | 3d | 4,672,724 | — | — | derivative | Form 4 ↗ | |
| ROIV | Option / conversion M | December 11, 2025 | December 15, 2025 | 4d | 1,869,691 | — | — | derivative | Form 4 ↗ | |
| ROIV | Other J | December 15, 2025 | December 15, 2025 | 0d | 478,708 | $22 | $10.6M | Form 4 ↗ | ||
| ROIV | Sell S | December 15, 2025 | December 15, 2025 | 0d | 353,745 | $22 | $7.8M | Form 4 ↗ | ||
| ROIV | Option / conversion M | December 15, 2025 | December 15, 2025 | 0d | 832,453 | $13 | $10.6M | Form 4 ↗ | ||
| ROIV | Other J | December 12, 2025 | December 15, 2025 | 3d | 2,696,866 | $22 | $59.2M | Form 4 ↗ | ||
| ROIV | Sell S | December 12, 2025 | December 15, 2025 | 3d | 1,975,858 | $22 | $43.4M | Form 4 ↗ | ||
| ROIV | Option / conversion M | December 12, 2025 | December 15, 2025 | 3d | 4,672,724 | $13 | $59.3M | Form 4 ↗ | ||
| ROIV | Other J | December 11, 2025 | December 15, 2025 | 4d | 1,095,550 | $22 | $23.7M | Form 4 ↗ | ||
| ROIV | Sell S | December 11, 2025 | December 15, 2025 | 4d | 774,142 | $22 | $16.8M | Form 4 ↗ | ||
| ROIV | Option / conversion M | December 11, 2025 | December 15, 2025 | 4d | 1,869,691 | $13 | $23.7M | Form 4 ↗ | ||
| ROIV | Sell S | November 17, 2025 | November 17, 2025 | 0d | 539,650 | $21 | $11.1M | Form 4 ↗ | ||
| ROIV | Sell S | November 14, 2025 | November 17, 2025 | 3d | 1,027,670 | $20 | $20.9M | Form 4 ↗ | ||
| ROIV | Sell S | November 13, 2025 | November 17, 2025 | 4d | 287,283 | $21 | $6.0M | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| December 15, 2025 | Form 4 | 0001635075-25-000006 | 12 | published | EDGAR ↗ |
| November 17, 2025 | Form 4 | 0001635075-25-000005 | 3 | published | EDGAR ↗ |
Other insiders at Roivant Sciences Ltd.
- Venker Eric President & Immunovant CEO 94 rows
- Sukhatme Mayukh President & CIO 49 rows
- Gold Daniel Allen Director 22 rows
- MANCHESTER KEITH S Director 22 rows
- Gline Matthew CEO 20 rows
- Epperly Melissa B, Director 19 rows
- QVT Financial LP Insider 19 rows
- Fitzgerald Meghan Director 18 rows
- Torti Frank President and Vant Chair 17 rows
- Pulik Richard CFO 14 rows
Everyone on file, with contracts and lobbying under the company's name: Roivant Sciences Ltd..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 2 | 15 | November 17, 2025 | December 15, 2025 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.